Hartington Pharmaceutical

2010

2009

Hartington puts down roots (Part I)

The pharmaceutical company plans to invest 10 million euros in a laboratory in Barcelona

MAR GALTÉS - Barcelona - La Vanguardia

Hartington is a company specialised in researching natural ingredients for the development of pharmaceutical products. Formed in 1996 in Barcelona by the Ukrainian Alex Levdanskyi and four other partners (three Georgians and a Spaniard, the lawyer Antonio Tradacete), it has two patents, one of which is already on the market. This is a product for the treatment of sinusitis based on European cyclamen extract and called Nasodren, Sinuforte or Fluirespira Forte, depending on the country it is sold in (Germany, Greece, Italy, and East European countries and former Soviet republics). The distribution licence in Spain was bought by Zambon. Hartington has a second skin treatment product “in the final phases of development,” says Levdanskyi.

“To go as fast as we would like to go, we would need to have a fully operational laboratory in Catalonia. The required investment could amount to 10 million euros; we can provide 3 million and we are looking for finance for the remaining 70 percent,” that is, 7 million euros, the company’s CEO explains. At present, Hartington is negotiating with Invest in Catalonia (Acc1Ó’s investment agency) and the Cedeti to take this project forward. “We can either build a new laboratory or buy an existing laboratory. It will be a R&D centre where 35 people will work and we would like to bring it on stream in about two years’ time.” Hartington currently outsources part of its production to a pharmaceutical company in Barberà del Vallès.

Keep reading the article